MoneyWorks4Me

Wanbury - Quaterly Results

28 Nov 2022 Evaluate
The revenue declined to Rs. 1239.55 millions for the quarter ended September 2022 as compared to Rs. 1240.94 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2022 is Rs. -8.90 millions as compared to Net Loss of Rs. -5.83 millions of corresponding quarter ended September 2021Operating Profit reported a sharp decline to 63.76 millions from 74.17 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 1239.55 1240.94 -0.11 2408.95 2519.56 -4.39 5111.86 3925.18 30.23
Other Income 7.80 3.07 154.07 27.15 6.12 343.63 15.08 24.04 -37.27
PBIDT 63.76 74.17 -14.04 52.67 142.71 -63.09 368.21 204.24 80.28
Interest 39.35 51.64 -23.80 72.44 101.84 -28.87 206.11 230.75 -10.68
PBDT 24.41 22.53 8.34 -19.77 40.87 -148.37 925.78 -26.51 -3592.19
Depreciation 31.51 27.80 13.35 61.85 54.19 14.14 114.50 97.54 17.39
PBT -7.10 -5.27 34.72 -81.62 -13.32 512.76 811.28 -124.05 -753.99
TAX 1.80 0.56 221.43 -0.27 1.12 -124.11 -3.46 2.00 -273.00
Deferred Tax 1.80 0.56 221.43 -0.27 1.12 -124.11 -3.46 -20.68 -83.27
PAT -8.90 -5.83 52.66 -81.35 -14.44 463.37 814.74 -126.05 -746.36
Equity 326.95 326.56 0.12 326.96 326.56 0.12 326.66 250.15 30.59
PBIDTM(%) 5.14 5.98 -13.94 2.19 5.66 -61.40 7.20 5.20 38.43
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..